The UC Davis Department of Dermatology has several ongoing clinical research studies. Click on the links below to learn more about the Investigators and their studies. For questions or additional information, please call us at (916) 734-1267 or send an e-mail to dermstudies@ucdavis.edu.

Actively Recruiting:

Psoriasis
PI: April Armstrong, M.D, M.P.H.
Title: Vascular Inflammation in Psoriasis Trial (A Trial to Determine the Effect of Psoriasis Treatment on Cardio Metabolic Disease)
Length of Study: 12 weeks

Psoriasis
PI: April Armstrong, M.D, M.P.H.
Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2
Length of Study: 5 years

Plaque Psoriasis
PI: April Armstrong, M.D, M.P.H.
Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Length of Study: 30 weeks

Psoriasis, Psoriatic Arthritis
PI: April Armstrong, M.D, M.P.H.
Title: Psoriasis and Psoriatic Arthritis Longitudinal Study
Length of Study: 5 years

Basal Cell Carcinoma
PI: April Armstrong, M.D, M.P.H.
Title: Investigating The Effects Of Short Pulse Light On Basal Cell Carcinomas (A Phase 1 Randomized Double-Blind Sham-Controlled [Placebo] Trial Of The Effect Of Illumination By The Photometics Scanstar On Human Basal Cell Carcinoma And Immediately Surrounding Tissue Prior To Excision)
Length of Study: 36 weeks

Mastocytosis
PI: Fu-Tong Liu, M.D, Ph.D.
Title: A 24-week With Possible Extension, Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 2-Parallel Group With a Randomization 1:1, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/day to Placebo in Treatment of Patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with Handicap,br />Length of Study: 24 weeks

Hidradenitis Suppurativa
PI: April Armstrong, M.D, M.P.H.
Title: A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa
Length of Study: 36 weeks

To find out more about dermatology clinical research studies, exactly what they are and how you can participate, click here.

Or contact us at:

Clinical Research Unit
3301 C Street, Suite 1400
Sacramento, CA 95816
Telephone: (916) 734-1267
Fax: (916) 442-5702
E-mail: dermstudies@ucdavis.edu